查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026789

癌症幹細胞療法市場預測至2034年：按癌症類型、治療方法、最終用戶和地區分類的全球分析

Cancer Stem Cells Therapy Market Forecasts to 2034 - Global Analysis By Cancer Type, Therapeutic Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 預測，全球癌症幹細胞治療市場預計到 2026 年將達到 69 億美元，並在預測期內以 12.2% 的複合年成長率成長，到 2034 年將達到 174 億美元。

癌症幹細胞療法是指開發和實施特異性針對癌症幹細胞（CSCs）的治療策略。癌症幹細胞是腫瘤內具有再生和分化能力的細胞群，它們參與腫瘤的發生、發展和治療抗藥性。癌症幹細胞療法旨在根除或抑制這些細胞的增殖，從而從根本上解決癌症病因並預防復發。

根據世界衛生組織（世衛組織）的數據，癌症是全球首要死因，2020 年造成約 1,000 萬人死亡。

個人化醫療正日益受到關注。

由於影響癌症進展的分子和遺傳因素十分複雜，治療模式轉移，開始根據每位患者的個別特徵量身定做治療方法。癌症幹細胞具有獨特的分子特徵，在腫瘤的發生和復發中發揮著至關重要的作用。精準醫療的理念與標靶這些特定細胞成分的目標完美契合，從而實現更精準有效的治療性介入。此外，人們已經清楚地認知到，根據每位患者獨特的基因組成客製化癌症幹細胞療法可以改善治療效果並減少副作用。

高昂的開發成本

癌症幹細胞研究的複雜性，加上臨床試驗和藥物核准的嚴格監管要求，需要大量的資金投入。為揭示癌症幹細胞的複雜性、進行臨床前試驗以及順利完成嚴苛的臨床試驗階段，需要進行大量的研究，這進一步增加了研發成本。此外，這些治療方法的成功率和商業性可行性的不確定性也增加了財務風險。製藥公司和研究機構面臨著如何在創新需求與將新型癌症幹細胞治療方法推向市場所需的財務負擔之間取得平衡的挑戰。

加大對癌症研究的投資

隨著我們對癌症生物學的認知不斷加深，癌症幹細胞在腫瘤發生發展中的關鍵作用日益受到重視。這種認知促使公共和私營部門加大研究投入，以揭示癌症幹細胞的複雜性並開發標靶治療。對創新治療方法的探索和腫瘤學領域科學知識的不斷深入，為新型癌症幹細胞療法的出現創造了有利環境。

倫理和監管問題

幹細胞研究的複雜性，包括胚胎幹細胞的應用，引發了關於治療性細胞來源和起源的倫理問題。這導致了持續的爭論，有時甚至引發監管限制，阻礙了特定幹細胞治療方法的開發和核准。此外，嚴格的臨床試驗和治療方法監管框架也加劇了研究人員和開發人員在將癌症幹細胞療法推向市場時所面臨的挑戰。

新冠疫情的感染疾病：

這次危機凸顯了創新治療方法（包括針對癌症幹細胞的治療方法）的迫切性，但研究活動、臨床試驗和醫療服務的中斷阻礙了市場成長。資源被轉移用於應對疫情、臨床試驗計劃的延誤以及患者招募方面的挑戰，都減緩了癌症幹細胞療法的研發步伐。此外，經濟的不確定性和醫療保健優先事項的轉變也影響了該領域的資金籌措和投資趨勢。

在預測期內，乳癌幹細胞治療領域預計將佔據最大佔有率。

由於其針對乳癌根本病因的標靶治療，乳癌幹細胞療法在整個預測期內佔據了最大的市場佔有率。針對這些特定細胞的治療能夠帶來更有效、更持久的療效，並降低癌症復發的風險。這種精準靶向癌幹細胞的策略提高了治療方法的整體療效，並促進了市場對該療法的接受度和需求的成長。此外，持續不斷的研究和進展，加深了我們對乳癌幹細胞分子機制的理解，進一步加速了創新治療方法的開發，吸引了投資，並推動了市場擴張。

預計在預測期內，基因治療領域將呈現最高的複合年成長率。

由於能夠特異性靶向和改造癌症幹細胞的先進基因技術，基因治療領域預計在預測期內將實現顯著成長。基因治療能夠導入治療性基因並操控現有基因，從而抑制對癌症幹細胞存活和增殖至關重要的訊號通路。此外，這種創新方法不僅提高了癌症治療的精準度，還能最大限度地減少對正常細胞的損傷並降低副作用。

市佔率最大的地區：

由於癌症發生率激增，尤其是乳癌、肺癌和大腸癌，亞太地區在整個預測期內佔據了最大的市場佔有率。這種沉重的疾病負擔促使人們增加對先進醫學研究和治療方法的投資，從而為癌症幹細胞療法的推廣創造了有利環境。此外，亞太地區醫療保健領域的快速技術進步和創新正在加速尖端治療方法的研發，包括針對癌症幹細胞的治療方法。

複合年成長率最高的地區：

亞太地區憑藉對研發的高度重視以及生物技術和製藥行業的快速發展，正蓄勢待發，並有望實現快速成長。這些因素特異性推動了針對癌症幹細胞的新型治療方法的發現，從而顯著改善治療效果。因此，在對更精準、更個人化治療方法的需求驅動下，癌症幹細胞療法的應用正在顯著增加。此外，該地區各國政府和監管機構正積極支持醫療基礎設施建設、研究舉措和臨床試驗，為新型治療方法快速融入主流癌症治療體系創造了有利環境。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球癌症幹細胞治療市場：依癌症類型分類

  • 腦癌幹細胞療法
  • 乳癌幹細胞療法
  • 大腸直腸癌幹細胞療法
  • 肺癌幹細胞療法
  • 前列腺癌幹細胞療法
  • 其他癌症

第6章 全球癌症幹細胞治療市場：依治療方法分類

  • 化療
  • 免疫療法
  • 放射線治療
  • 幹細胞移植
  • 標靶治療
  • 分化療法
  • 基因治療
  • 奈米顆粒治療方法
  • 聯合治療
  • 其他治療方法

第7章 全球癌症幹細胞治療市場：依最終用戶分類

  • 癌症研究機構
  • 醫院
  • 專科診所
  • 大學醫院
  • 醫療保健專業人員
    • 外科醫生
    • 放射腫瘤學家
    • 血液科醫生
  • 其他最終用戶

第8章 全球癌症幹細胞治療市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第9章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第10章：公司簡介

  • AbbVie Inc.
  • AdnaGen AG
  • Astellas Pharma Inc.
  • Bristol Myers Squibb
  • Cancer Stem Cells Co., Ltd
  • Gamida Cells
  • Glycosyn LLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novadip Biosciences
  • Novartis AG
  • OncoMed Pharmaceuticals
  • Pfizer Inc
  • Roche Holdings AG
  • Stemline Therapeutics, Inc.
  • Thermo Fisher Scientific, Inc
Product Code: SMRC24716

According to Stratistics MRC, the Global Cancer Stem Cells Therapy Market is accounted for $6.9 billion in 2026 and is expected to reach $17.4 billion by 2034 growing at a CAGR of 12.2% during the forecast period. The Cancer Stem Cells Therapy involves the development and implementation of therapeutic strategies specifically targeting cancer stem cells (CSCs), a subpopulation of cells within tumors believed to possess self-renewal and differentiation capabilities. These cells are implicated in tumor initiation, progression, and treatment resistance. Cancer stem cell therapy aims to eradicate or inhibit the growth of these cells, thereby addressing the root cause of cancer and preventing relapse.

According to World Health Organization (WHO), cancer was the leading cause of death worldwide, accounting for nearly 10 million deaths in 2020.

Market Dynamics:

Driver:

Growing emphasis on personalized medicine

Due to the intricate molecular and genetic factors influencing cancer advances, there is a paradigm shift towards tailoring treatments based on individual patient characteristics. Cancer stem cells, with their distinct molecular profiles, play a pivotal role in tumor development and recurrence. The emphasis on personalized medicine aligns seamlessly with the objective of targeting these specific cellular components, allowing for more precise and effective therapeutic interventions. Additionally, by customizing cancer stem cell therapies to the unique genetic makeup of each patient, the potential for improved treatment outcomes and reduced side effects becomes apparent.

Restraint:

High development costs

The intricate nature of cancer stem cell research, coupled with the stringent regulatory requirements for clinical trials and drug approvals, contributes to substantial financial investments. The extensive research needed to unravel the complexities of cancer stem cells, conduct preclinical studies, and progress through rigorous clinical trial phases amplifies development expenses. Moreover, the uncertainty associated with the success and commercial viability of these therapies adds to the financial risk. Pharmaceutical companies and research institutions face the challenge of balancing the imperative to innovate with the financial burden of bringing novel cancer stem cell therapies to market.

Opportunity:

Increasing investment in oncology research

As the understanding of cancer biology evolves, there is a growing recognition of the pivotal role played by cancer stem cells in tumor initiation and progression. This realization has prompted a surge in research funding, both from public and private sectors, dedicated to unraveling the complexities of cancer stem cells and developing targeted therapies. The heightened focus on identifying innovative treatment modalities and advancing scientific knowledge in oncology creates a conducive environment for the emergence of novel cancer stem cell therapies.

Threat:

Ethical and regulatory concerns

The intricate nature of stem cell research, including the use of embryonic stem cells, raises ethical considerations surrounding the source and derivation of cells for therapy. This has prompted ongoing debates and, at times, regulatory restrictions, creating hurdles in the development and acceptance of certain stem cell-based treatments. Additionally, stringent regulatory frameworks governing clinical trials and therapeutic approvals contribute to the challenges faced by researchers and developers in bringing cancer stem cell therapies to market.

Covid-19 Impact:

While the crisis emphasized the urgent need for innovative therapies, including those targeting cancer stem cells, disruptions in research activities, clinical trials, and healthcare services have impeded the market's trajectory. The redirection of resources toward pandemic-related efforts, delays in clinical trial timelines, and challenges in patient recruitment have slowed down the pace of cancer stem cell therapy development. Additionally, economic uncertainties and shifts in healthcare priorities have influenced funding availability and investment patterns in the sector.

The breast cancer stem cells therapy segment is expected to be the largest during the forecast period

Breast Cancer Stem Cells Therapy segment dominated the largest share of the market over the forecast period due to its targeted approach in treating breast cancer at its roots. The therapeutic focus on these specific cells allows for more effective and sustained treatment outcomes, reducing the likelihood of cancer relapse. This precision in targeting cancer stem cells enhances the overall efficacy of therapies, contributing to increased adoption and demand in the market. Additionally, ongoing research and advancements in understanding the molecular mechanisms of breast cancer stem cells further fuel the development of innovative therapies, attracting investments and driving market expansion.

The gene therapy segment is expected to have the highest CAGR during the forecast period

Gene Therapy segment is estimated to witness lucrative growth over the projection period due to the advanced genetic techniques to specifically target and modify cancer stem cells. Gene therapy enables the introduction of therapeutic genes or the manipulation of existing ones to disrupt the signaling pathways crucial for the survival and proliferation of cancer stem cells. Furthermore, this innovative approach not only enhances the precision of cancer treatment but also minimizes damage to normal cells, reducing side effects.

Region with largest share:

Asia Pacific region commanded the largest market share over the extrapolated period due to a surge in cancer incidence, with breast, lung, and colorectal cancers being particularly prevalent. This high disease burden has spurred increased investments in advanced medical research and treatment modalities, creating a conducive environment for the expansion of cancer stem cell therapies. Moreover, the Asia Pacific region has experienced rapid technological advancements and innovation in the healthcare sector, fostering the development of cutting-edge therapies, including those targeting cancer stem cells.

Region with highest CAGR:

Asia Pacific region is projected to grow at a rapid pace owing to a strong focus on research and development, coupled with a burgeoning biotechnology and pharmaceutical industry, has paved the way for the discovery of novel therapeutic approaches that specifically target cancer stem cells, enhancing treatment efficacy. As a result, there is a notable increase in the adoption of cancer stem cell therapies, driven by the demand for more precise and tailored treatment options. Additionally, governments and regulatory bodies in the region are also actively supporting advancements in healthcare infrastructure, research initiatives, and clinical trials, creating an environment conducive to the rapid integration of novel therapies into mainstream cancer care.

Key players in the market

Some of the key players in Cancer Stem Cells Therapy market include AbbVie Inc., AdnaGen AG, Astellas Pharma Inc., Bristol Myers Squibb, Cancer Stem Cells Co., Ltd, Gamida Cells, Glycosyn LLC, Johnson & Johnson, Merck & Co., Inc., Novadip Biosciences, Novartis AG, OncoMed Pharmaceuticals, Pfizer Inc, Roche Holdings AG, Stemline Therapeutics, Inc. and Thermo Fisher Scientific, Inc.

Key Developments:

In December 2023, Novartis receives FDA approval for Fabhalta(R) (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH. Significant unmet need remains in PNH, a chronic and rare blood disorder; despite anti-C5 therapy, a large proportion of patients can remain anemic and dependent on blood transfusions

In July 2023, US FDA approves expanded indication for Novartis Leqvio(R) (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease. Leqvio can now be used earlier in LDL-C treatment as an adjunct to diet and statin therapy for patients who have not had a cardiovascular event but are at an increased risk of heart disease

Cancer Types Covered:

  • Brain Cancer Stem Cells Therapy
  • Breast Cancer Stem Cells Therapy
  • Colorectal Cancer Stem Cells Therapy
  • Lung Cancer Stem Cells Therapy
  • Prostate Cancer Stem Cells Therapy
  • Other Cancer Types

Therapeutic Types Covered:

  • Chemotherapy
  • Immunotherapy
  • Radiation Therapy
  • Stem Cell Transplantation
  • Targeted Therapy
  • Differentiation Therapy
  • Gene Therapy
  • Nanoparticle-Based Therapies
  • Combination Therapies
  • Other Therapeutic Types

End Users Covered:

  • Cancer Research Institutes
  • Hospitals
  • Specialty Clinics
  • Academic Medical Centers
  • Healthcare Professionals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Stem Cells Therapy Market, By Cancer Type

  • 5.1 Introduction
  • 5.2 Brain Cancer Stem Cells Therapy
  • 5.3 Breast Cancer Stem Cells Therapy
  • 5.4 Colorectal Cancer Stem Cells Therapy
  • 5.5 Lung Cancer Stem Cells Therapy
  • 5.6 Prostate Cancer Stem Cells Therapy
  • 5.7 Other Cancer Types

6 Global Cancer Stem Cells Therapy Market, By Therapeutic Type

  • 6.1 Introduction
  • 6.2 Chemotherapy
  • 6.3 Immunotherapy
  • 6.4 Radiation Therapy
  • 6.5 Stem Cell Transplantation
  • 6.6 Targeted Therapy
  • 6.7 Differentiation Therapy
  • 6.8 Gene Therapy
  • 6.9 Nanoparticle-Based Therapies
  • 6.10 Combination Therapies
  • 6.11 Other Therapeutic Types

7 Global Cancer Stem Cells Therapy Market, By End User

  • 7.1 Introduction
  • 7.2 Cancer Research Institutes
  • 7.3 Hospitals
  • 7.4 Specialty Clinics
  • 7.5 Academic Medical Centers
  • 7.6 Healthcare Professionals
    • 7.6.1 Surgeons
    • 7.6.2 Radiation Oncologists
    • 7.6.3 Hematologists
  • 7.7 Other End Users

8 Global Cancer Stem Cells Therapy Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 AbbVie Inc.
  • 10.2 AdnaGen AG
  • 10.3 Astellas Pharma Inc.
  • 10.4 Bristol Myers Squibb
  • 10.5 Cancer Stem Cells Co., Ltd
  • 10.6 Gamida Cells
  • 10.7 Glycosyn LLC
  • 10.8 Johnson & Johnson
  • 10.9 Merck & Co., Inc.
  • 10.10 Novadip Biosciences
  • 10.11 Novartis AG
  • 10.12 OncoMed Pharmaceuticals
  • 10.13 Pfizer Inc
  • 10.14 Roche Holdings AG
  • 10.15 Stemline Therapeutics, Inc.
  • 10.16 Thermo Fisher Scientific, Inc

List of Tables

  • Table 1 Global Cancer Stem Cells Therapy Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Cancer Stem Cells Therapy Market Outlook, By Cancer Type (2023-2034) ($MN)
  • Table 3 Global Cancer Stem Cells Therapy Market Outlook, By Brain Cancer Stem Cells Therapy (2023-2034) ($MN)
  • Table 4 Global Cancer Stem Cells Therapy Market Outlook, By Breast Cancer Stem Cells Therapy (2023-2034) ($MN)
  • Table 5 Global Cancer Stem Cells Therapy Market Outlook, By Colorectal Cancer Stem Cells Therapy (2023-2034) ($MN)
  • Table 6 Global Cancer Stem Cells Therapy Market Outlook, By Lung Cancer Stem Cells Therapy (2023-2034) ($MN)
  • Table 7 Global Cancer Stem Cells Therapy Market Outlook, By Prostate Cancer Stem Cells Therapy (2023-2034) ($MN)
  • Table 8 Global Cancer Stem Cells Therapy Market Outlook, By Other Cancer Types (2023-2034) ($MN)
  • Table 9 Global Cancer Stem Cells Therapy Market Outlook, By Therapeutic Type (2023-2034) ($MN)
  • Table 10 Global Cancer Stem Cells Therapy Market Outlook, By Chemotherapy (2023-2034) ($MN)
  • Table 11 Global Cancer Stem Cells Therapy Market Outlook, By Immunotherapy (2023-2034) ($MN)
  • Table 12 Global Cancer Stem Cells Therapy Market Outlook, By Radiation Therapy (2023-2034) ($MN)
  • Table 13 Global Cancer Stem Cells Therapy Market Outlook, By Stem Cell Transplantation (2023-2034) ($MN)
  • Table 14 Global Cancer Stem Cells Therapy Market Outlook, By Targeted Therapy (2023-2034) ($MN)
  • Table 15 Global Cancer Stem Cells Therapy Market Outlook, By Differentiation Therapy (2023-2034) ($MN)
  • Table 16 Global Cancer Stem Cells Therapy Market Outlook, By Gene Therapy (2023-2034) ($MN)
  • Table 17 Global Cancer Stem Cells Therapy Market Outlook, By Nanoparticle-Based Therapies (2023-2034) ($MN)
  • Table 18 Global Cancer Stem Cells Therapy Market Outlook, By Combination Therapies (2023-2034) ($MN)
  • Table 19 Global Cancer Stem Cells Therapy Market Outlook, By Other Therapeutic Types (2023-2034) ($MN)
  • Table 20 Global Cancer Stem Cells Therapy Market Outlook, By End User (2023-2034) ($MN)
  • Table 21 Global Cancer Stem Cells Therapy Market Outlook, By Cancer Research Institutes (2023-2034) ($MN)
  • Table 22 Global Cancer Stem Cells Therapy Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 23 Global Cancer Stem Cells Therapy Market Outlook, By Specialty Clinics (2023-2034) ($MN)
  • Table 24 Global Cancer Stem Cells Therapy Market Outlook, By Academic Medical Centers (2023-2034) ($MN)
  • Table 25 Global Cancer Stem Cells Therapy Market Outlook, By Healthcare Professionals (2023-2034) ($MN)
  • Table 26 Global Cancer Stem Cells Therapy Market Outlook, By Surgeons (2023-2034) ($MN)
  • Table 27 Global Cancer Stem Cells Therapy Market Outlook, By Radiation Oncologists (2023-2034) ($MN)
  • Table 28 Global Cancer Stem Cells Therapy Market Outlook, By Hematologists (2023-2034) ($MN)
  • Table 29 Global Cancer Stem Cells Therapy Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.